Skip to Content

Posts tagged with "Drug Industry History"

  • Business and Markets

    The Hollywood Analogy

    Yesterday’s drug-research-is-hard screed brought a lot of responses, and I wanted to address some particular points that came up. On Twitter, Alex Tabarrok of Marginal Revolution advanced the Hollywood Analogy. I’ve used this one myself; it leads off a talk that I put together a few years ago. The model for a movie studio is… Read More
  • Clinical Trials

    I Do Hate To Tell You This, But. . .

    The timing of this report from the FDA is surely no accident, but it’s always a good time to think about this: the great majority of all drugs that enter clinical trials fail. They fail because they don’t do anyone any good, or because what good they might do is outweighed by some serious and… Read More
  • Business and Markets

    Out of Ideas?

    The Wall Street Journal came out with a series of articles on innovation in the US, and the biopharma industry features quite a bit in them. The lead one is an overview, with the theme of “The US economy’s hidden problem is that we’re out of big ideas”, and there’s another one specifically on Sanofi… Read More
  • Business and Markets

    Productivity Over the Years

    The last couple of years have been very good for the number of drug approvals, reversing a rather worrying trend. But are these data points themselves enough to qualify as a reversal? That’s what John Carroll is asking here, pointing out that even the traditional end-of-the-year flurry of approvals doesn’t look likely to rescue the num… Read More
  • Business and Markets

    Pfizer Says They Won’t Break Up

    Pfizer has been mulling over the idea of turning into at least two Pfizers for a long time now, but they’re out with an announcement this morning that they’ve decided that their current structure is the one that will help them be the best Pfizer that they can be. That’s going to disappoint a lot of… Read More
  • Drug Assays

    A Quick Survey of the Landscape

    I think, at this point in the history of medicinal chemistry, that we’re now trying to define just what the limits of med-chem might be. By that, I mean small molecules, as opposed to biologics. The early days of the field were naturally a lot more wide open, since there were so many targets that… Read More
  • Drug Industry History

    Company Time For Your Own Ideas, Or Not?

    Over the years, at many R&D-driven companies, there have been official/unofficial policies that researchers could spend some percent of their time pursuing their own ideas, versus their official projects and goals. You hear different figures, especially when it comes to past glories, but there are definitely companies that have made this a stat… Read More
  • Business and Markets

    Infinity’s Research, From Someone Who Was There

      Here’s a look from the inside at Infinity Pharmaceuticals, whose R&D operations hit the wall just recently. Keith Robison knows the company and its targets well, having worked there until about five years ago, and he provides a perspective that some others in the readership will have experienced as well: So it was a… Read More
  • Business and Markets

    Infinity’s Difficult History

    Infinity Pharmaceuticals today announced that it’s shutting down R&D operations. This comes after disappointing clinical results for a PI3K inhibitor it’s been developing (duvelisib), news which has sent the company’s stock down (at this moment) nearly 70%. And that comes after the 2012 failure of another clinical candidate, s… Read More
  • Clinical Trials

    Are Things Getting Any Better in the Clinic?

    Here’s an updated look at clinical success rates in the biotech industry, from the BIO industry organization. They’re looking at only company-sponsored programs aimed at FDA registration, nothing investigator-sponsored, and it’s a big data set: This is the largest study of clinical drug development success rates to date. Over the… Read More